Key Highlights

  • Unaudited Q1 FY27 Revenue rose $1.7 million, or 4.8%, EBITDA rose $1.01 million, or 197.5%, and operational expenditure fell $685,000, or 9.5%, against the prior corresponding period.
  • Medical cannabis dispensing volumes rose 19% on the June quarter, while Bupa patient consultations at Doctors on Demand are winding down.
  • The company has finalised a Three Horizon Plan, with details to be shared at the AGM on 27 November 2026, and states its focus is returning the Business to profitability.

Vitura Health Limited (ASX:VIT), a diversified digital health business, released a Q1 FY2027 operational update on 13 October 2026. The company says first-quarter performance was ahead of its expectations across revenue, EBITDA and operating expenditure. The revenue, EBITDA and operating expenditure figures are unaudited.

Headline figures

Against the prior corresponding period, revenue was up $1.7 million, or 4.8%, EBITDA was up $1.01 million, or 197.5%, and operational expenditure was down $685,000, or 9.5%. The release does not state absolute EBITDA or revenue figures, though it describes the company's focus as a return to profitability.

Three Horizon Plan

Vitura has finalised a Three Horizon Plan, endorsed by the Board, setting out phased short, medium and long-term growth. Horizon One is a 12 to 18 month focus on improving patient access through improved distribution and fulfilment capability, enhancing platforms, systems and processes, embedding a consistent clinical governance framework, reviewing contracting and Margin stability, and rigorous expense discipline. More detail is planned for the Annual General Meeting on 27 November 2026.

Candor and Canview

Growth came from both Candor's business-to-consumer clinical services and Canview's business-to-business ordering and prescribing platform. Candor's patient consultations increased, including check-up consultations. Medical cannabis dispensing volumes were up 19% on Q4 FY26, contributing to revenue growth, with margins on those sales also improving. Canview's promotional program for pharmacies delivered what the company describes as higher sales.

Doctors on Demand

Doctors on Demand revenue exceeded expectations, with consultation numbers helped by continued Bupa consultations, while underlying volumes excluding Bupa International patients also stayed above expectations. The Bupa International Student transition is complete and the International Visitor transition began on 9 September 2026. With Bupa consultations winding down, the company says it is aligning operating infrastructure to anticipated volumes and building business-to-business and consumer pipelines.

Emerging markets and caution

Nicotine vaping product revenue rose 107% against the prior corresponding period, with forecasts expected to exceed FY27 expectations. Cortexa continues to Supply product supporting Emyria's expansion into Sydney, and the addition of Curaleaf to the supplier network broadened the product offering. The company acknowledges that industry pressures and continued recovery work will require a disciplined effort, and that its statements are forward-looking and subject to risks outside its control.

Business lines described

Vitura operates Candor, a consumer clinical services business, and Canview, a business-to-business ordering and prescribing platform that sells and distributes roughly 600 therapeutic product and device SKUs from roughly 70 international and domestic brands. Canview is described as an end-to-end ecosystem combining several software-as-a-service providers for inventory control, invoicing, customer management and reporting. Doctors on Demand provides 24/7 GP telehealth.

Limits of the update

The release gives percentage and dollar changes against the prior corresponding period rather than absolute revenue, EBITDA or cash figures, and states the numbers are unaudited. It does not give FY27 guidance. The company says more detail on the Three Horizon Plan is due at the 27 November 2026 AGM, and notes that forward-looking statements are subject to risks outside its control.